Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
Go back to Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine| (NASDAQ: PRAX) | Delayed: 302.53 -0.86 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $303.39 | 52 Week High | $ | |||
| Open | $298.50 | 52 Week Low | $ | |||
| Day High | $307.65 | P/E | N/A | |||
| Day Low | $296.36 | EPS | $ | |||
| Volume | 282,350 | |||||
